title: Endothelin expression in human megakaryoblastic leukemia cell lines and normal platelet precursors.
abstract: The aim of the present investigation was to determine whether endothelin (ET) could be expressed in and released from the human leukemia megakaryoblastic cell lines HEL, MEG-01, DAMI and the normal human platelet progenitors. Using the reverse transcriptase-polymerase chain reaction (RT-PCR) on total RNA isolated from the cells, we amplified a cDNA of the expected size (453 bp). Southern-blotting hybridization revealed that RT-PCR products from the cell lines were specific of ET-1 mRNA. Immunocytochemical analyses highlighted immunoreactive ET-1 in the cytoplasm of these cells which also released the mature peptide. ET-1 release from the three cell lines was increased by thrombin exposure. Although MEG-01 cells express ET receptors, ET-1, the selective ETB agonist sarafotoxin 6C and the non-selective ET-receptor antagonist PD 142893 showed no proliferative or antiproliferative action in basal or stimulating medium. This indicated a lack of autocrine ET-mediated effect on growth. These results demonstrate for the first time that human megakaryoblastic leukemia cell lines and normal bone marrow platelet precursors express ET-1 mRNA and release the mature peptide.
authors.affiliation: INSERM U 300, Faculté de Pharmacie, Montpellier, France.
authors.forename: M N
authors.initials: MN
authors.lastname: Mathieu
authors.forename: D
authors.initials: D
authors.lastname: Vittet
authors.forename: M F
authors.initials: MF
authors.lastname: Laliberté
authors.forename: F
authors.initials: F
authors.lastname: Laliberté
authors.forename: I
authors.initials: I
authors.lastname: Nonotte
authors.forename: D
authors.initials: D
authors.lastname: Hamroun
authors.forename: J M
authors.initials: JM
authors.lastname: Launay
authors.forename: C
authors.initials: C
authors.lastname: Chevillard
mesh_terms: D001792:Blood Platelets / Q000166:cytology / Q000378:metabolism*; D015139:Blotting, Southern; D002455:Cell Division / Q000187:drug effects; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000235:genetics* / Q000378:metabolism / Q000494:pharmacology; D015870:Gene Expression; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007947:Leukemia, Megakaryoblastic, Acute / Q000378:metabolism*; D008533:Megakaryocytes / Q000166:cytology / Q000378:metabolism*; D009842:Oligopeptides / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000378:metabolism; D013917:Thrombin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014757:Viper Venoms / Q000494:pharmacology
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D009842:Oligopeptides; D012333:RNA, Messenger; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D014757:Viper Venoms; C057354:sarafotoxins s6; C076213:PD 142893; D013917:Thrombin